Key result
In patients with acute coronary syndrome, higher BNP levels independently predicted cardiovascular events at 10 months, with the highest tercile conferring an adjusted RR of 4.91 (95% CI 2.62-9.22).
Why the study?
Does the addition of B-type natriuretic peptide (BNP) to the GRACE score improve risk stratification for cardiovascular events in patients with acute coronary syndrome?
Cohort (n=449)
Does the addition of B-type natriuretic peptide (BNP) to the GRACE score improve risk stratification for cardiovascular events in patients with acute coronary syndrome?
Relative Risk: 4.91 (95% CI 2.62–9.22)
The combined use of bedside BNP levels and the GRACE score significantly enhances risk stratification for adverse cardiovascular events in patients with acute coronary syndrome compared to the GRACE score alone.
BNP may enhance ACS risk stratification beyond clinical scores; leaves open additive value to GRACE pending prospective validation.
BACKGROUND: In acute coronary syndrome (ACS), both the Global Registry of Acute Coronary Events (GRACE) score and B-type natriuretic peptide (BNP) predict cardiovascular events. However, it is unknown how BNP compares with GRACE and how their combination performs in ACS. METHODS: The authors recruited 449 consecutive ACS patients and measured admission GRACE score and bedside BNP levels. The main outcome measure was all-cause mortality, readmission with ACS or congestive heart failure (defined as a cardiovascular event) at 10 months from presentation. RESULTS: Of the 449 patients, 120 patients presented with ST-elevation myocardial infarction (MI) (27%). There were 90 cardiovascular events at 10 months. Both higher GRACE terciles and higher BNP terciles predicted cardiovascular events. There was a significant but only partial correlation between the GRACE score and log BNP (R = 0.552, p<0.001). On multivariate analyses, after adjusting for the GRACE score itself, increasing BNP terciles independently predicted cardiovascular events (second BNP tercile adjusted RR 2.28 (95% CI 1.15 to 4.51) and third BNP tercile adjusted RR 4.91 (95% CI 2.62 to 9.22)). Patients with high GRACE score-high BNP were more likely to experience cardiovascular events at 10 months (RR 6.00 (95% CI 2.40 to 14.83)) compared to those with high GRACE score-low BNP (RR 2.40 (95% CI 0.76 to 7.56)). CONCLUSION: In ACS, most but not all of our analyses suggest that BNP can predict cardiovascular events over and above the GRACE score. The combined use of both the GRACE score and BNP can identify a subset of ACS patients at particularly high risk. This implies that both the GRACE score and BNP reflect somewhat different risk attributes when predicting adverse prognosis in ACS and their synergistic use can enhance risk stratification in ACS to a small but potentially useful extent.
No takes yet. Share an insight, caveat, or question.
Ang et al. (2009) conducted a cohort in Acute coronary syndrome (ACS) (n=449). B-type natriuretic peptide (BNP) and GRACE score vs. Lower BNP terciles / lower GRACE scores was evaluated on All-cause mortality, readmission with ACS or congestive heart failure (cardiovascular event) (RR 4.91, 95% CI 2.62-9.22). In patients with acute coronary syndrome, higher BNP levels independently predicted cardiovascular events at 10 months, with the highest tercile conferring an adjusted RR of 4.91 (95% CI 2.62-9.22).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: